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dehydrogenase (SSADH) downregulation. Enhancing 
GHB levels via SSADH downregulation or GHB supple-
mentation triggered cell conversion into a less aggressive 
phenotypic state. GHB affected adult glioblastoma cells 
with varying molecular profiles, along with cells from 
pediatric pontine gliomas. In all cell types, GHB acted by 
inhibiting α-ketoglutarate-dependent Ten–eleven Trans-
locations (TET) activity, resulting in decreased levels of 
the 5-hydroxymethylcytosine epigenetic mark. In patients, 
low SSADH expression was correlated with high GHB/α-
ketoglutarate ratios, and distinguished weakly prolifera-
tive/differentiated glioblastoma territories from prolifera-
tive/non-differentiated territories. Our findings support an 
active participation of metabolic variations in the genesis of 
tumor heterogeneity.
Abstract Cell populations with differing proliferative, 
stem-like and tumorigenic states co-exist in most tumors 
and especially malignant gliomas. Whether metabolic vari-
ations can drive this heterogeneity by controlling dynamic 
changes in cell states is unknown. Metabolite profiling 
of human adult glioblastoma stem-like cells upon loss of 
their tumorigenicity revealed a switch in the catabolism 
of the GABA neurotransmitter toward enhanced produc-
tion and secretion of its by-product GHB (4-hydroxybu-
tyrate). This switch was driven by succinic semialdehyde 
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Introduction
Tumor development is a complex process mixing clonal 
selection and dynamic changes in cell states including phe-
notypic differentiation of cancer stem cells, which leads to 
tumors composed of heterogeneous cancer cell populations 
[20, 21]. De novo glioblastoma (GBM), the most common 
and malignant primary brain tumor in adults, is a para-
digmatic example of heterogeneous tumors. This malig-
nant glioma remains incurable, with all patients relapsing 
despite aggressive multimodal therapies [43]. Its heteroge-
neity is illustrated by the coexistence of territories enriched 
in weakly or actively proliferative cells [10], and of cells 
with variable expression of molecular markers, differences 
in morphological features of differentiation, and variable 
tumorigenicity [37, 40]. Recent single cell genomic and 
transcriptomic analysis further documented this heteroge-
neity [37, 41]. However, the role of metabolism in the gen-
esis of tumor cells and/or territories with differing states of 
aggressiveness remains unexplored. Following the recent 
discovery that the differentiation of embryonic stem cells 
(ESC) depends on fluctuations in the levels of the metabo-
lite α-ketoglutarate (α-KG) [8], we envisaged that changes 
in metabolism could drive cancer cell phenotypic differen-
tiation rather than be a passive adaptation to differentiation.
To address this issue, we focused on GBM stem-like 
cells, which share with ESC transcription factors such as 
Nanog that govern their behavior [9]. These cancer cells, 
endowed with self-renewal, differentiation, tumor-initiating 
properties and resistance to current therapies, are active 
drivers of tumor growth [9]. Importantly, they can oscil-
late between a non-differentiated, aggressive state and a 
differentiated, less aggressive state in response to environ-
mental cues [5, 39].
We exploited first our recent discovery that differenti-
ated, weakly proliferative GBM cells express the micro-
RNA cluster miR-302-367, the expression of which 
triggers GBM stem-like cell exit from their stem and tumo-
rigenic state [15]. This cell model served as a starting para-
digm to pinpoint metabolic changes of potential relevance 
and to identify their molecular source. Metabolome pro-
filing revealed an unexpected increase in the GABA by-
product GHB (4-hydroxybutyrate), which we discovered to 
be caused by downregulation of the mitochondrial enzyme 
SSADH. We then determined whether increasing GHB 
levels might be sufficient per se to alter the cell properties, 
using additional and independent GBM and deep infiltrat-
ing glioma (DIPG) cells. Combining metabolite meas-
urements, genomic and pharmacological manipulations, 
in vivo experiments, bioinformatics analyses of independ-
ent GBM datasets, and analysis of patients’ tumor tissues, 
we discovered that fluctuation in the levels of GHB suf-
fices to switch malignant glioma cell from a proliferative 
and aggressive behavior to a more differentiated and less 
aggressive state.
Materials and methods
All the figures were prepared using Adobe Illustrator 
(Adobe Systems).
Human tissues
Glioblastoma samples from adult patients were obtained 
from surgical resections. For metabolite measurements and 
immunohistochemical analysis, glioblastoma fragments 
were subjected to multisampling.
Cell culture
GBM stem-like cells TG1, TG16, GBM-M, R633 cells 
were isolated from neurosurgical biopsy samples of human 
GBM (Table S1), and their stem-like and tumor-initiating 
properties characterized as previously reported [4, 42, 49, 
53]. TG1-miR was derived from TG1 as described [15]. 
GBM stem-like cells 6240**, stably expressing a lucif-
erase construct, GBM stem-like cells 5706**, and JolMa 
cells were characterized as described [7, 46]. No muta-
tion in IDH1 or IDH2 coding regions was found (Table 
S1). TP54, TP80, TP83, TP84 stem-like cells with a K27M 
H3F3A mutation [58], were isolated from pediatric DIPG 
and characterized as previously described [52]. Molecular 
profiles were obtained with transcriptome analysis using 
Affymetrix Exon 1.0S array (3 independent biological 
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replicates), and proneural, classical or mesenchymal sub-
type determined with respect to the classification of the 
TCGA established with a 840 genes list [55]. UT7 leuke-
mia cell line was transduced with lentiviral vector encod-
ing doxycycline-inducible human TET2-GFP cDNA (Fig. 
S6E). TG1 stem-like cells were transduced with lentiviral 
vectors encoding doxycycline-inducible human wild-type 
or catalytically deficient form of TET2-GFP cDNA (Fig. 
S6F). TG1, 6240**, 5706** and TP54 stem-like cells 
were transduced with lentiviral vectors encoding a control 
or an ALDH5A1 shRNA construct (GeneCopeia, Tebu, 
France). In relevant experiments, cells were treated with 
GHB or valproate (both from Sigma) or their vehicles (cell 
medium).
Metabolite measurement by mass spectrometry (MS)
Cells and media were harvested 96 h post-seeding (cell 
half-doubling time = 4.5, TG1, and 8 days, TG1-miR). 
Cell pellets were washed in PBS before freezing. Media 
and cell samples (n = 6) were extracted and analyzed on 
the GC/MS and LC/MS/MS platforms of Metabolon, Inc. 
(Durham, NC, USA) as previously described [45]. Fol-
lowing normalization to total protein values for cell data 
(Bradford assay), log transformation, and imputation with 
minimum observed values for each compound, Welch’s 
two-sample t tests were used to identify metabolites that 
differed significantly between experimental groups. The 
level of significance was set at p < 0.05. Each metabolite 
was mapped to pathways based on the Kyoto Encyclope-
dia of Genes and Genomes (KEGG) (http://www.genome.
jp/kegg/‎), the human metabolome database (http://www.
hmdb.ca), and literature mining. Targeted analyses of GHB 
(4-hydroxybutyrate) and 2-HG (2-hydroxyglutarate) were 
performed with GC–MS/MS (300MS, Brüker) in the clini-
cal chemistry laboratory at Necker Enfants Malades Hospi-
tal (Paris, France). For metabolite measurements in tissues, 
glioblastoma fragments from adult patients were subjected 
to multisampling. Each sample was divided into two mirror 
pieces: one snap-frozen, the second reserved for immuno-
histological characterization. Tissue punches from weakly 
proliferative/differentiated (PLOW/D+) and proliferative/
non-differentiated (PHIGH/D−) glioblastoma territories were 
obtained from the snap-frozen pieces.
Cell death evaluation
Cell death was evaluated using the propidium iodide (PI) 
exclusion test. The cells were incubated with PI (10 µg/106 
cells) for 10 min at 4 °C, and the percentage of cells con-
taining PI was measured using FACS (ARIA II, BD Bio-
sciences, France).
Clonality and self‑renewal evaluation
Cells were plated at one cell/well (Nunc, 96-deep well 
plate, non-treated), and treated with 10 mM of GHB each 
48 h over four weeks. The cells were then dissociated, 
and seeded at one cell/well. The percentage of wells 
containing spheres was scored. At least 500 cells were 
analyzed for each culture. For extreme limiting dilution 
assays (ELDA), cells were plated in 96-well plates at 1, 
5, 10, 20, 50, and 100 cells/well/100 μl as previously 
described [4]. The percentage of wells with neurospheres 
was determined after 10 and 21 days. The analysis of the 
frequency of sphere-forming cells, a surrogate property 
of brain cancer stem-like cells [18] was performed with 
software available at http://bioinf.wehi.edu.au/software/
elda/ [25].
Cell cycle analysis
Cells were incubated with BrdU (5-Bromo-2′-
deoxyuridine, 10 µM, Invitrogen) for 3 h, and analyzed 
after DAPI staining using an ARIA II (BD Biosciences, 
France). Analysis was performed on 10,000-gated events. 
Violet laser (405 nm) and Pacific Blue filter were used for 
DAPI detection, and Red laser (640 nm) and APC filter for 
BrdU detection. Data analysis and figure generation were 
performed using the FACS Diva version 6.1.2 program (BD 
Biosciences, France).
Cell adherence assay
Cells were plated in 96-well plates (BD Biosciences, BD 
BioCoat Poly-d-Lysine) at a density of 5 × 103 cells/well. 
The number of adherent cells was counted after 24 h of 
incubation and expressed in percentage of the total cell 
numbers. Images were acquired on a digital camera (DXM 
1200, Nikon, USA) using AxioVision 4.6 Software (Labo-
ratory Imaging, Ltd).
siRNA transfection
Cell transfection was achieved with the Amaxa Nucleofec-
tor Electroporator using the Nucleofector program A-020 
(Amaxa Biosystems, Gaithersburg, MD, USA). Cells were 
transfected by electroporation with 1 μM of control siRNA 
(Ambion® Silencer Negative Control, Cat#AM4611), 
or anti-ALDH5A1 siRNAs (Ambion® Cat#16,708, ID 
si15460, Cat#16,708 ID si15462), or anti-TET2 siRNAs 
(Ambion® Cat#4392420, ID si29443). The transfection was 
performed using the L transfection solution (AMAXA). 
The cells were chocked twice (at day 0 and day 3) and col-
lected at day 6.
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Luciferase reporter assays
Cells were transfected with Renilla Luciferase mRNA and 
Firefly luciferase mRNA containing either the wild-type 
form of ALDH5A1-3′UTR or a mutant form of ALDH5A1-
3′UTR with a deletion of the miR-302 putative target 
sequence (ALDH5A1-3′UTR-DEL). The quantification of 
Renilla and Firefly luciferase activity was performed using 
the Dual-Luciferase Reporter Assay System (Promega, 
France), according to manufacturer’s instructions. Renilla 
luciferase was used for internal normalization of Firefly 
activity values.
Immunoblotting
Cells were harvested, washed with PBS and cell lysis 
was performed in 50 mM Tris–HCl pH 7.4 buffer con-
taining 1% Triton X-100, 150 mM NaCl, 0.5 mM EGTA, 
0.5 mM EDTA and anti-protease cocktail (Complete Pro-
tease inhibitor Cocktail Tablets, Roche, France). Protein 
extracts (30 μg) were separated by SDS-PAGE and trans-
ferred to Hybond-C Extra nitrocellulose membranes (GE 
Healthcare, USA). The following antibodies were used for 
immunoblotting: anti-Nanog (Cell Signaling, 1:1000), anti-
p21 (Santa Cruz Biotechnology, 1:200), anti-Actin (Mil-
lipore Chemicon, 1:10,000), anti-SSAR (Novus biological, 
1:2000), anti-ABAT1 (GABA-T) (Sigma Aldrich, 1:2500), 
anti-GAD65 (Abcam, 1:500), anti-GAD67 (Abcam, 
1:500), anti-HOT (Sigma, 1:2000), anti-GLUD1 (Sigma, 
1:2000), and anti-SSADH (Novus Biological, 1:2000). The 
secondary antibodies were anti-mouse IgG (Santa Cruz 
Biotechnology, 1:10,000), anti-rabbit IgG (GE Health-
care, 1:10,000) and anti-goat IgG (Santa Cruz Biotechnol-
ogy, 1:10,000). Signal detection was performed with the 
ECL + chemiluminescence detection system (PerkinElmer, 
France). Densitometric analysis was achieved using ImageJ 
software.
Immunocytochemistry
Cells were harvested, PBS washed, smeared on Super-
Frost slides (Fischer Scientific, France), and fixed in ice 
cold methanol for 20 min at −20 °C. Following fixation, 
cells were washed with PBS, and incubated for 30 min. at 
room temperature in PBS containing 0.3% Triton X-100 
and 5% BSA (Sigma). The following primary antibodies 
were incubated overnight at 4 °C: Nanog (1:200, R&D), 
Olig2 (1:200, R&D), GFAP (1:5000, Dako), GLT-1/EEAT2 
(1:200, Santa Cruz), ß3-Tubulin (1:3000, Covance), Map-2 
(1:1000, Millipore). Secondary antibodies were incubated 
at room temperature for 1 h (Alexa Fluor® 488, Alexa 
Fluor® 555, Molecular Probes, 1:2000). Immunostaining 
was analyzed with a fluorescent microscope equipped with 
an ApoTome module (Axioplan 2, Zeiss). Images were 
acquired on a digital camera using AxioVision 4.6 Software 
(Laboratory Imaging, Ltd) and prepared using Adobe Pho-
toshop software (Adobe Systems, San Jose, CA). Immuno-
fluorescent signals were analyzed with Volocity 3D Image 
Analysis software (PerkinElmer, France) using single opti-
cal 240 nm sections.
Immunohistochemistry
Morphologic examination was performed on Hematoxy-
lin- and Eosin-stained sections (3–4 μm). Immunolabeling 
was performed using an automated system (Autostainer 
Dako, Glostrup Denmark) with the following primary anti-
bodies: anti-Ki67 (MIB-1, Dako, prediluted), anti-Olig2 
(goat polyclonal, R&D Systems, 1:500) and anti-GFAP 
(Dako, 1:4000). Deparaffinization, rehydration and antigen 
retrieval were performed using the pretreatment module 
PTlink (Dako). SSADH immunostaining was achieved fol-
lowing overnight incubation with anti-SSADH (Novus Bio-
logical, 1:100) at 4 °C. Immunostaining was scored by a 
pathologist (FBV).
DNA sequencing, q‑PCR
RNA was extracted from the cells with RNeasy Mini Kit 
(Qiagen, Hilden, Germany, http://www.qiagen.com), sub-
mitted to an on-column DNase digestion (RNase-Free 
DNase Set, Qiagen) and retrotranscribed (QuantiTect 
Reverse Transcription Kit, Qiagen). PCR was performed 
using Platinum® Taq DNA Polymerase High Fidelity (Inv-
itrogen). The PCR products were purified and sequenced 
(Biofidal, Vaulx en Velin, France, http://biofidal.com). 
Q-PCR assays were performed using an ABI Prism 7700 
Sequence Detection system (Perkin-Elmer Applied Biosys-
tems), and the SYBR Green PCR Core Reagents kit (Per-
kin-Elmer Applied Biosystems). Transcripts of the TBP 
gene encoding the TATA box-binding protein were used for 
normalization.
5‑hydroxymethylcytosine (5‑hmC) 
and 5‑methylcytosine (5‑mC) detection
5-hmC and 5-mC were quantified using dot blot assays 
with anti-5-hmC antibody (Active Motif, Carlsbad, CA, 
1:10,000) and anti-5-mC antibody (Millipore Calbiochem, 
Darmstadt, Germany, 1:2000). DNA was spotted onto 
nylon Hybond N+ 53 membranes (Amersham) and fixed 
by U.V. cross-linking. Membranes were air-dried, blocked 
and incubated with anti-5-hmC or anti-5-mC antibodies 
and horseradish peroxidase-conjugated secondary antibody 
(anti-rabbit IgG 1:10,000, GE Healthcare, anti-mouse IgG 
1:10,000, Santa Cruz Biotechnology). Signal detection was 
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performed with the ECL + chemiluminescence detection 
system (PerkinElmer, France). Densitometric analysis was 
achieved using ImageJ software.
Intracranial xenografts
6240** GBM stem-like cells transduced with a luciferase-
encoding lentivirus, 5706** GBM stem-like cells and TP54 
DIPG stem-like cells stably expressing GFP were used. 
100,000 (6240**), 50,000 (5706**) and 25,000 (TP54) 
cells were injected stereotaxically into the striatum of anes-
thetized 8- to 9-week-old Nude mice (Harlan Laborato-
ries), using the following coordinates: 0 mm posterior and 
2.5 mm lateral to the bregma, and 3 mm deep with respect 
to the surface of the skull. 16 mice were grafted with 
6240** cells transduced with a shControl construct and 15 
mice with a shALDH5A1 construct. Luminescent imaging 
was performed on an IVIS Spectrum (Perkin-Elmer), after 
intra-peritoneal injection of luciferin. Total flux (photons 
per second) values were obtained by imaging mice 14 and 
49 days after stereotaxic cell injection and quantified with 
Live Image 4.0 software. Xenografts of GFP-expressing 
5706** and TP54 transduced with a shControl construct 
or a shALDH5A1 construct were each performed into 3 
(5706**) or 4 (TP54) mice per group. Mice were sacri-
ficed at 64 (5706**) or 71 (TP54) days post-graft, and the 
numbers of GFP-expressing cells determined. The animal 
maintenance, handling, surveillance, and experimentation 
were performed in accordance with and approval from the 
Comité d’éthique en expérimentation animale Charles Dar-
win N°5 (Protocol #3113).
Statistical analysis
Statistical analyses were done with Prism 6.0 software 
(GraphPad) using unpaired t test with Welch’s correc-
tion, or one-sample t test when appropriate unless oth-
erwise indicated. Significance threshold was set at 
p < 0.05. Mean ± SD are shown. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
Results
GBM stem‑like cells differentiation is accompanied 
by ALDH5A1 downregulation, which reprograms 
GABA metabolism toward enhanced GHB production
Metabolic rearrangements in differentiated GBM stem-like 
cells were investigated using unbiased global metabolomic 
profiling of the TG1 cell line, which was isolated from an 
IDH1 and 2 wild-type primary GBM (Table S1). We com-
pared naïve cells and cells stably expressing miR-302-367 
(referred to as TG1-miR) that are deprived of stem and 
tumorigenic properties [15], and enriched in differentia-
tion markers (see [15] and Fig. S1). Gas chromatography/
mass spectrometry (GC/MS) and liquid chromatography/
MS/MS analysis of whole cell extracts and secreted culture 
media showed that all identified metabolic intermediates 
and endpoint products of energy metabolic pathways, i.e., 
glycolysis, tricarboxylic acid (TCA) cycle, and anaplerotic 
glutaminolysis were significantly reduced in TG1-miR, as 
exemplified by α-KG a key metabolite of the TCA cycle 
that can be replenished through anaplerotic reactions (Table 
S2).
This overall reduction in TG1 energy metabolism upon 
loss of their stem and tumorigenic properties was accom-
panied by a broad deregulation of GABA neurotransmit-
ter metabolism (Fig. 1a, b). Decreased GABA levels were 
associated with increased levels of its metabolic by-prod-
ucts GHB, 2-hydroxyglutarate (2-HG), and 4-guanidinobu-
tanoate (4-GDB) (Table S2). As a result, GABA by-prod-
ucts to α-KG ratios were increased in TG1-miR (Fig. 1a). 
Since GHB levels were increased in both intra- and extra-
cellular compartments, we further focused on understanding 
the cause for the elevated production of GHB. As depicted 
in Fig. 1b, glutamate is the entry point of GABA synthesis 
pathway. It can either be converted into α-KG by glutamate 
dehydrogenase (or aminotransferases), or into GABA by 
glutamate decarboxylases (GAD67 and GAD65). GABA 
transaminase (GABA-T) catalyzes GABA conversion into 
succinic semialdehyde. The succinic semialdehyde reduc-
tase (SSA reductase/SSAR) is responsible for the synthesis 
of GHB from succinic semialdehyde, whereas hydroxyacid-
oxoacid transhydrogenase (HOT) is responsible for GHB 
degradation. HOT catalyzes a concomitant reaction that 
additionally produces succinic semialdehyde and 2-HG 
from α-KG. In silico analysis identified putative miR-302-
367 recognition sites in the mRNA of three enzymes of 
this pathway, i.e., GABA transaminase/GABA-T, hydroxy-
oxoacid transhydrogenase/HOT, succinic semialdehyde 
dehydrogenase/SSADH (Fig. S2A). Only SSADH protein 
levels were markedly reduced in TG1-miR compared to 
TG1 (Fig. 1c, Fig. S2B). The transcript levels of ALDH5A1, 
which encodes SSADH, were also strongly reduced 
(Fig. 1d). To confirm the direct targeting of the 3′ UTR 
region of ALDH5A1 mRNA by miR-302, we employed 
TG1-miR and TG1 cells expressing a Renilla luciferase 
expression construct containing the ALDH5A1-3′UTR. 
Luciferase activity was strongly reduced in TG1-miR com-
pared to TG1 (Fig. 1e). Deletion of miR-302 putative target 
sequence in the 3′UTR of ALDH5A1 mRNA (ALDH5A1-
3′UTR-DEL) prevented the binding of the miR, and res-
cued luciferase activity (Fig. 1e). SSADH converts succinic 
semialdehyde into succinate, fuelling thus the TCA cycle 
and thereby limiting the amounts of substrate for SSAR, 
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the enzyme responsible for GHB synthesis (Fig. 1b). Since 
SSAR levels were unchanged in TG1-miR (Fig. S2B), we 
verified whether reduced SSADH expression was sufficient 
to increase GHB levels. SSADH downregulation by siRNA 
targeting of ALDH5A1 mRNA (Fig. 1f) caused accumula-
tion of GHB not only in stem-like cells of adult GBM but 
also in stem-like cells of infant DIPG, a form of high-grade 
glioma with a poor prognosis [58] (Fig. 1g). No change was 
observed in the levels of 2-HG, the other GABA by-product 
(Fig. S3). To further test the link between ALDH5A1 down-
regulation and enhanced GHB production, we used val-
proate to inhibit SSADH activity. Valproate has long been 
known to inhibit SSADH activity [54, 57], before being 
found to also inhibit histone deacetylases [19]. The adult 
GBM 6240** and DIPG TP54 cell lines were treated with 
5 mM valproate. Mass spectrometry measurements showed 
a five- to sixfold increase in GHB intra-cellular levels in 
valproate-treated cells compared to control cells (Fig. S4). 
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Altogether, these results show that decreased SSADH 
expression is sufficient to increase GHB levels.
Using neurosurgical samples of patient tumors, we then 
compared SSADH expression and GHB/α-KG ratios in 
GBM territories characterized by low or high prolifera-
tive and differentiation features. Coherently to our in vitro 
observations, we found that SSADH staining prevailed in 
proliferative/non-differentiated GBM territories (PHIGH/D−) 
containing mitotic and Olig2 + tumor cells (Fig. 1h, upper 
panels and Fig. S5A). On the opposite, SSADH expres-
sion was scant in non-proliferative/differentiated GBM ter-
ritories (PLOW/D+) characterized by rare mitotic cells and 
lack of Olig2 expression (Fig. 1h, lower panels and Fig. 
S5A). Interestingly, SSADH was also detected in normal 
cells albeit at a lower intensity than in tumor cells of pro-
liferative/non-differentiated GBM territories (Fig. S5B). Of 
note, destruction of the normal underlying axonal network 
distinguishing the solid tumor tissue from infiltrative peri-
tumoral tissue was confirmed using neurofilament stain-
ing (Fig. S5C). In addition, GC–MS/MS analysis showed 
that GHB/α-KG ratios tended to be higher in these GBM 
territories characterized by rare mitotic cells (Fig. 1i). 
Altogether, these results support the pathological relevance 
of variations in GHB levels in the context of human GBM.
GHB inhibits proliferation of GBM and DIPG stem‑like 
cells
To further probe the coherence between the in vitro find-
ings and the observations in the patient tumors, we assayed 
GHB effects on GBM and DIPG cells focusing first on the 
expression of the transcription factor Olig2 and prolifera-
tion. These assays were performed while maintaining the 
cells in stem-media containing the EGF and bFGF mito-
gens. GHB inhibited the expression of Olig2 (Fig. 2a, b). 
Olig2 is required for the proliferation and tumorigenic-
ity of adult GBM cells through repression of the inhibi-
tor of cell cycle progression p21/CDKN1A [35]. Accord-
ingly, Western blotting showed up-regulated p21 levels in 
GHB-treated cells (Fig. 2c), and upon siRNA-mediated 
ALDH5A1 downregulation (Fig. S6A).
Inhibition of the self-renewal properties of adult GBM 
cells (TG1, 6240**, R633) and infant DIPG cells (TP54, 
TP83) accompanied these changes, as determined through 
the generation of secondary and tertiary spheres from sin-
gle cells derived from primary spheres (Fig. 2d) or extreme 
limiting dilution assays (Fig. S6B). In presence of GHB, 
the percentage of cells yielding secondary and tertiary 
spheres dropped from 75–90 to 3–7, and 0–3%, respec-
tively (Fig. 2d). In coherence with these findings, GHB 
inhibited proliferation of all 7 adult GBM and 4 infant 
DIPG cells tested. Cell numbers were reduced by 40–70% 
(Fig. 2e), while cell survival was unaffected (Fig. S6C and 
D). Cell cycle analysis of TG1 and TP54 cells showed 
a two- to threefold reduction in the number of cells in S 
phase (Fig. 2f, g), further confirming GHB inhibitory 
effects on cancer stem-like cell proliferation. Consist-
ently, enhanced GHB production due to siRNA-mediated 
ALDH5A1 downregulation in adult GBM (TG1) and infant 
DIPG (TP54) stem-like cells was accompanied by reduced 
cell proliferation similar to GHB treatment alone (Fig. 2h). 
Reduced proliferation rates were also observed in cells 
transduced with shALDH5A1 compared to shControl (Fig. 
S6E). Furthermore, enhanced GHB production resulting 
from valproate inhibition of SSADH activity also resulted 
in robust inhibition of cell proliferation (Fig. S6F).
SSADH‑driven GHB accumulation induces GBM 
and DIPG stem‑like cell differentiation into less 
aggressive cells
We further evaluated the relevance of our findings for the 
patient tumors by using independent dataset to probe links 
between SSADH expression and stem cell-like features 
that have been associated with glioma cell tumorigenicity 
Fig. 1  Loss of stem and tumorigenic properties by GBM stem-like 
cells is accompanied with GABA metabolism deregulation char-
acterized by enhanced GHB levels. a Increased GABA by-products 
to α-KG ratios in TG1-miR compared to TG1. The “+” sign repre-
sents the mean value in the whisker box. Mean ± SD, n = 6 inde-
pendent biological samples. b Schematic reconstruction of metabolic 
pathways with green and red boxes signaling metabolites decreased 
or increased in TG1-miR compared to TG1, respectively. Enzyme 
names are within grey boxes. When relevant, the corresponding gene 
designation is indicated below the enzyme name. SSADH: succinic 
semialdehyde dehydrogenase. SSAR succinic semialdehyde reduc-
tase. c Downregulation of the ALDH5A1 protein product SSADH 
in TG1-miR. Western blot analysis. SSADH MW, 57 kDa; Actin 
MW, 42 kDa. Mean ± SD, n = 3 independent biological samples. d 
Decreased ALDH5A1 mRNA levels in TG1-miR compared to TG1. 
Q-PCR assays. Mean ± SD, n = 3 independent biological sam-
ples. e Targeting of the ALDH5A1 transcript by miR-302. Expres-
sion of Renilla Luciferase mRNA containing the wild-type form of 
ALDH5A1-3′UTR is strongly reduced in TG1-miR compared to 
TG1. Deletion of miR-302 putative target sequence in the 3′UTR of 
ALDH5A1 mRNA (ALDH5A1-3′UTR-DEL) prevents the binding of 
the miR, and rescues luciferase activity. n = 3 independent biologi-
cal samples. f Decreased SSADH levels in GBM and DIPG stem-
like cells (TG1, TP54) upon ALDH5A1 downregulation with siRNAs 
(siA). siC (control siRNA). Mean ± SD, n = 3 independent biologi-
cal samples. RDU, relative densitometry units. g ALDH5A1 down 
regulation results in enhanced GHB intra-cellular levels. Mean ± SD, 
n = 3 independent biological samples. h SSADH immunoreactive 
cells are enriched in proliferative/non-differentiated GBM territories 
(PHIGH/D−) and rare in non-proliferative/differentiated (PLOW/D+) 
tumor territories of patients’ GBM, as revealed by immunohisto-
chemical staining of Ki67, Olig2, and GFAP. HES: hematoxylin and 
eosin staining. Scale bar 100 µm. i GHB/α-KG ratios in proliferative/
non-differentiated (PHIGH/D−) and weakly proliferative/differenti-
ated territories (PLOW/D+) of patient GBM. GC–MS/MS analysis. 
Mean ± SD, n = 5 independent patient’s GBM neurosurgical sam-
ples
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[9]. The analysis of the TCGA transcriptome dataset of 
484 untreated primary GBM was performed using the R2 
Genomics Analysis and Visualization Platform (http://
r2.amc.nl). The analysis disclosed a correlation posi-
tive for ALDH5A1, and negative for AKR7A2 (encoding 
SSAR), with a majority of genes belonging to the KEGG 
pathway «Signaling pathways regulating pluripotency 
of stem cells» (Fig. 3a). 122 of the 142 genes listed in 
this category were detected in the dataset. 61 were sig-
nificantly correlated with ALDH5A1 (48 positive/13 nega-
tive) and 38 with AKR7A2 (3 positive/35 negative). The 
same correlations were also found with the R2 platform’ 
gene category named «cancer gene census only» that 
contains 487 cancer-related genes (Fig S7A). Of the 371 
cancer-related genes detected in the TCGA dataset, 190 
were significantly correlated with ALDH5A1 (130 posi-
tive/60 negative) and 178 with AKR7A2 (23 positive/155 
negative). In addition, the analysis of published tran-
scriptome dataset of early-passage (P3) GBM cells either 
devoid of or endowed with self-renewing and tumor-initi-
ating properties [32], revealed downregulated ALDH5A1, 
and conversely up-regulated AKR7A2 expression in non-
tumorigenic cells compared to tumorigenic cells (Fig. 3b). 
Using serum addition as well as growth factor removal as 
another means to promote cell exit from the stem state, 
we also observed downregulated ALDH5A1 (Fig. S7B 
and C). These results led us to determine GHB effects 
on the expression of the stem transcription factor Nanog, 
Fig. 2  GHB inhibits GBM and DIPG stem-like cell prolifera-
tion and self-renewal. a Immunocytochemical detection of Olig2. 
1-week GHB 10 mM. Scale bars 10 µm. b Quantification of Olig2 
nuclear immunofluorescent (IF) signal. n = 4 independent biologi-
cal samples. c Upregulated expression of p21/CDKN1A in GBM 
and DIPG stem-like cells (10 mM GHB, 1 week, Western blot assay, 
mean ± SD, n = 3 independent biological samples). p21 MW, 
21 kDa; Actin MW, 42 kDa. RDU relative densitometry units. d 
GHB inhibits self-renewal of GBM (TG1) and DIPG (TP54) stem-
like cells. Mean ± SD, n = 3 independent biological samples. e GHB 
inhibits cell growth of stem-like cells isolated from adult GBM and 
pediatric DIPG. Total numbers of viable cell evaluated after 1-week 
10 mM GHB treatment. Mean ± SD, n = 3 independent biological 
samples. f, g GHB arrests cell cycle. f Example of cell cycle FACS 
analysis of GHB-treated TG1 GBM stem-like cells. BrdU labels 
cells having undergone DNA replication. DAPI is an index of DNA 
content. g Quantification of the cell cycle analyses. Mean ± SD, 
n = 3 independent biological samples. h ALDH5A1 downregula-
tion in GBM (TG1) and DIPG (TP54) stem-like cells inhibits cell 
proliferation. siA (ALDH5A1 siRNA) versus siC (control siRNA), 
mean ± SD, n = 3 independent biological samples
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which controls the stem-like and tumorigenic properties 
of GBM cells [34, 39, 59]. Immunofluorescent imag-
ing showed a robust decrease in nuclear Nanog signal in 
GHB-treated GBM cells with either mesenchymal (TG1, 
TG16), or classical profiles (JolMa, 6240**) as well as in 
infant DIPG cells with pro-neural profiles (TP54, TP80) 
(Fig. 3c, d). Similar to GHB treatment, siRNA-mediated 
ALDH5A1 downregulation in TG1 (adult GBM) and TP54 
(infant DIPG) cells decreased Nanog nuclear localization 
(Fig. 3e). Decreased Nanog expression was confirmed 
by Western blotting (Fig. 3f, TG1), and FACS analysis 
(Fig. 3g, h, TG1, R633, TP83). We further found that 
GHB stimulated GBM stem-like cell adhesion on permis-
sive substrates with formation of membrane extensions 
(Fig. 3i), and increased numbers of cells expressing the 
differentiation markers ß3-Tubulin and MAP2, or GFAP 
and EAAT2/GLT1 upon transfer in pro-neuronal or pro-
astroglial differentiation media, respectively (Fig. S7D). 
In a coherent manner, ALDH5A1 downregulation with 
shRNA, or valproate inhibition of SSADH activity were 
also accompanied with increased expression of differen-
tiation markers (Fig. S7E and F).
Altogether, these results showed that SSADH-driven 
GHB accumulation repressed proliferation, clonality and 
stem-like features of malignant glioma cells. We there-
fore determined whether these repressive effects affected 
in vivo tumor development using orthotopic xenografts 
of GBM (6240**, 5706**) and DIPG (TP54) stem-like 
cells stably expressing either shControl or shALDH5A1 
(Fig. S8). GBM stem-like cells 6240**, which stably 
express luciferase, were used for bioluminescent imag-
ing. Results showed reduced tumor burden in mice grafted 
with 6240**-shALDH5A1 compared to mice grafted 
with 6240**-shControl cells (Fig. 3j). In addition, a sig-
nificant improvement in survival of the mice grafted with 
6240**-shALDH5A1 cells was observed (Kaplan–Meier 
analysis, Fig. S9A). Decreased tumor burden was also 
observed with grafts of 5706**-shALDH5A1 and TP54-
shALDH5A1, as shown by cell counting (Figs. 3k, S9B).
Inhibition of TET activity mediates GHB repressive 
effects on GBM and DIPG stem‑like cells
GHB is naturally present in the brain at low concentra-
tions and acts as an inhibitory neuromodulator through the 
GABA receptor GABABR [12], and a GABAAR sub-class 
[1]. Using TG1 cells, we found that agonists of GABAAR 
(Isoguvacine hydrochloride) or GABABR (Baclofen) did 
not modify GBM cell proliferation whereas GABAAR or 
GABABR antagonists (Gabazine and Hydroxysaclofen) did 
not prevent GHB inhibition of cell proliferation (Fig. S10). 
GHB action being independent from GABA receptors, we 
investigated an intracellular mode of action.
GC–MS/MS analysis showed that GHB treatment led to 
increase in its intra-cellular levels (Fig. 4a). GHB penetra-
tion inside the cells, and the similarity of its chemical struc-
ture to that of α-KG (Fig. 4b), suggested that GHB could 
target α-KG-dependent enzymes such as Ten–eleven Trans-
locations (TETs). These nuclear enzymes are needed for 
ESC maintenance in the stem state, and for reprogramming 
somatic cells into induced pluripotent stem cell (iPSC) [11, 
14, 17]. They notably act by oxidizing 5-methylcytosine 
(5-mC) into 5-hmC [17], which has been shown recently 
to recruit a methylosome complex needed for glioblastom-
agenesis [51].
The evaluation of mRNA levels showed TET2 to be the 
most abundant of the three TET isoforms in the cells stud-
ied here (Fig. S11A). Dot immunoblotting of DNA extracts 
showed a marked reduction in 5-hmC levels in GHB-
treated GBM (TG1) as in DIPG stem-like cells (TP54) 
compared to control conditions, whereas 5-mC levels were 
unchanged (Fig. 4c, d). Similar results were obtained using 
siALDH5A1-transfected TG1 and TP54 cells (Fig. 4e). 
Compared to TG1, we also found reduced 5-hmC levels in 
TG1-miR (Fig. S11B) and in TG1 treated with serum (Fig. 
S11C), a well-known inducer of GBM cell differentiation 
into less tumorigenic cells. Notably, GHB did not alter 
5-hmC levels in human fetal neural stem cells (NSC) (Fig. 
S11D).
Since GHB did not inhibit expression of TET2, or of 
the other TET isoforms (Fig. 5a), we pursued the study of 
GHB effect on TET2 enzymatic activity. To further con-
firm GHB inhibition of TET2 activity, we first used a UT7 
leukemic cell line stably overexpressing TET2 in a doxy-
cycline-dependent manner (Fig. 5b). In UT7 cells, 5-hmC 
was only detected upon induction of TET2 expression, and 
GHB strongly reduced 5-hmC levels (Fig. 5c). The same 
results were obtained with TG1 cells engineered to express 
either a doxycycline-inducible wild-type or a catalytically 
defective TET2 (Fig. 5d). Enhanced 5-hmC formation was 
only observed upon induction of wild-type TET2 expres-
sion, and was counteracted in presence of GHB (Fig. 5e). 
The analysis of TET2 structure confirmed the presence of 
a GHB binding pocket within TET2. As previously men-
tioned, α-KG is a co-factor required for TET2 oxidative 
activity. The crystal structure of TET2 has shown localiza-
tion of α-KG binding site in the C-terminal domain of the 
protein [24]. To identify the site of GHB binding pocket in 
TET2, we performed in silico docking analysis on the Gal-
axyWEB platform (http://galaxy.seoklab.org/softwares/gal-
axydock.html [22]). We first confirmed the existence of a 
unique binding pocket for α-KG, formed by 11 amino acids 
located as expected in TET2 C-terminal domain (Fig. 5f). 
A unique binding pocket was also found for GHB (Fig. 5g), 
almost identical to the α-KG binding pocket: of the 11 
amino acids forming the α-KG binding pocket, only 153A 
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was not included in the GHB binding pocket (Fig. 5h). Cal-
culated docking energies were similar for GHB and α-KG 
(−6.228 and −8.761 kcal/mole, respectively).
Finally, to ascertain further the link between TETs and 
GHB, we used siRNA to downregulate TET2 (Fig. 6a). 
TG1 and TP54 cells were used as examples of GBM 
and DIPG cells, since GHB had the same effects on all 
the cells we had examined. TET2 downregulation had 
effects comparable to GHB treatment or ALDH5A1 
downregulation, i.e., reduced 5-hmC levels without 
significant change in 5-mC levels (Fig. 6b), decreased 
Nanog nuclear signals (Fig. 6c) and reduced cell prolif-
eration (Fig. 6d).
Altogether, these results showed that GHB decreases 
5-hmC levels by antagonizing TET activity, and that TET2 
participates in the mechanisms by which GHB induces 
GBM and DIPG cell differentiation into less aggressive 
cells (Fig. 6e).
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Discussion
Understanding the molecular mechanisms underlying the 
genesis of heterogeneous cancer cell populations in brain 
tumors is likely to have profound impacts on therapeutic 
management. Here, we provide evidence that variations in 
expression of a single metabolic enzyme support cancer 
cell variegation by promoting GBM stem-like cell differen-
tiation, hence favoring the genesis of cancer cell sub-popu-
lations with alleviated aggressiveness.
We show that elevating GHB intra-cellular levels 
through GHB supplementation, SSADH downregulation 
with si or shRNA or its pharmacological inhibition with 
valproate induces differentiation of stem-like cells isolated 
from distinct GBM and DIPG with differing profiles and 
genomic alterations. GHB inhibited cell self-renewal, pro-
liferation, and expression of stem markers by repressing 
TET-mediated formation of 5-hmC. Analysis of transcrip-
tome datasets from independent cohort of GBM tissues 
(TCGA) or cells [32] further associated high ALDH5A1 
expression with stem-like and cancerous behaviors within 
the context of GBM. Importantly, we disclosed strikingly 
distinct SSADH expression over GBM territories distin-
guished notably by their contents in proliferating cells. 
SSADH was enriched in non-differentiated, proliferative 
GBM territories compared to differentiated, weakly pro-
liferative territories, which had scarce SSADH expression. 
These differing SSADH expression patterns were asso-
ciated with elevated GHB/α-KG ratios in differentiated 
territories. These results, associated with reduced tumor-
initiating properties of GBM cells with repressed SSADH 
expression in orthotopic xenograft assays, support the func-
tional relevance of GABA metabolism reprogramming in 
the context of the patient tumors. In addition, the increase 
in GHB extra-cellular levels accompanying increased GHB 
Fig. 4  GHB accumulates in GBM and DIPG stem-like cells and 
decreases levels of the 5-hydroxymethylcytosine epigenetic mark. 
a Increased intracellular GHB levels detected by mass spectrometry 
following GHB supplementation (n = 3 independent biological sam-
ples). b Chemical structure of α-KG and GHB. c Example of 5-hmC 
and 5-mC detection by dot immunoblotting of DNA extracts from 
control (C) and GHB-treated GBM stem-like cells (TG1). Methylene 
blue (MB) was used as a loading control. d GHB decreases 5-hmC 
levels in GBM (TG1) and DIPG (TP54) stem-like cells without 
changing 5-mC levels. Densitometric analysis of dot immunoblotting 
of DNA extracts (10 mM GHB, 1 week). Mean ± SD, n = 3 (TG1) 
and n = 4 (TP54) independent biological samples. e ALDH5A1 
downregulation in GBM (TG1) or DIPG (TP54) stem-like cells 
results in decreased 5-hmC levels in face of unchanged 5-mC levels. 
Mean ± SD, n = 4 (TG1) and n = 3 (TP54) independent biological 
samples
Fig. 3  GHB promotes GBM and DIPG stem-like cell differentia-
tion and decreases tumor burden. a Positive and negative correlation 
of ALDH5A1 and AKR7A2 expression with stemness genes (p < 0.01 
after correction for multiple testing with false discovery rate). Gene 
ontology (GO) analysis using transcriptomes of 484 untreated pri-
mary human GBM of the TCGA dataset. Of the 142 listed in KEGG 
pathway category «Signaling pathways regulating pluripotency of 
stem cells» , 122 were detected in the dataset. 61 were significantly 
correlated with ALDH5A1 (48 positive/13 negative) and 38 with 
AKR7A2 (3 positive/35 negative). b Opposite regulation of ALDH5A1 
and AKR7A2 transcript levels in cells with and without self-renewing 
and tumor-initiating properties (SR/TI) isolated from 4 human GBM 
[32]. Mean ± SD. c–h GHB inhibits Nanog expression. c Examples of 
immunocytochemical detection of Nanog. 1-week GHB 10 mM. Scale 
bars 10 µm. (d) Quantification of nuclear Nanog immunofluorescent 
(IF) signal. Mean ± SD, n = 3 independent biological samples. Micro-
photographs illustrate 240 nm single optical sections of TG1 cells 
immunostained for Nanog. e Decreased Nanog expression in response 
to ALDH5A1 downregulation. siA, ALDH5A1 siRNA. siC, control 
siRNA. Mean ± SD, n = 4 independent biological samples. f Nanog 
Western blot assay with protein extracts from control (Cont) and 
10 mM GHB-treated TG1 GBM stem-like cells (1-week treatment). 
Nanog MW, 47 kDa; Actin MW, 42 kDa. n = 3 independent biological 
samples. RDU, relative densitometry units. g FACS analysis of Nanog 
immunofluorescent signal. Grey and red lines delineate unstained 
TG1 cells in control and GHB-treated conditions, respectively. h Fold 
change of mean fluorescent intensity of Nanog signal per cell (con-
trol vs 1 week-GHB 10 mM), as determined by FACS. TG1 and R633 
GBM stem-like cells. TP83 DIPG stem-like cells. Mean ± SD, n = 4 
independent biological samples. i GHB promotes cell adherence and 
membrane extension. Microphotograph of TG1 GBM stem-like treated 
with 10 mM GHB for 24 h and quantification of the numbers of adher-
ing cells. Mean ± SD, n = 6 independent biological samples (TG1), 
n = 3 (5706**), n = 3 (TP83). Scale bar 100 µm. j Bioluminescent 
analyses of tumor growth initiated by grafting 6240** GBM stem-
like cells transduced with a luciferase construct and a control (shC) or 
ALDH5A1 (shA) shRNA construct. 49 days post-graft. Quantification 
of the bioluminescent signals. Mean ± SD, n = 15 mice per group. 
Photographs correspond to examples of bioluminescent in vivo images 
of tumors in mice. k Quantification of tumor cells numbers following 
xenografts of GFP-expressing 5706** GBM or TP54 DIPG stem-like 
cells transduced with a control or ALDH5A1 shRNA construct. Mice 
were killed at 64 (5706**) or 71 (TP54) days post-graft, and the num-
bers of GFP-expressing cells determined. Mean ± SD, n = 3 (5706**) 
and 4 mice (TP54) per group
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Fig. 5  GHB decreases 5-hydroxymethylcytosine levels via inhi-
bition of TET2 activity. a GHB does not reduce expression of TET 
isoforms. Q-PCR assay. Mean ± SD, n = 4 (TG1) and 3 (TP54) 
independent biological samples. b Doxycycline-dependent TET2 
expression in the leukemic UT7 cell line. UT7 cells were treated for 
12 h with doxycycline (Dox) at a final concentration of 1 µg/mL. 
TET2 mRNA levels were assayed using Q-PCR. Dox-treated versus 
-untreated UT7, mean ± SD, n = 3 independent biological samples. 
c GHB inhibits TET2 activity in the leukemic UT7 cell line express-
ing TET2 in a doxycycline-dependent manner. 12 h 10 mM GHB. 
5-hmC levels determined by DNA dot immunoblotting. GHB-treated 
vs control UT7, mean ± SD, n = 3 independent biological samples. 
d Doxycycline-dependent TET2 expression in GBM stem-like cells 
(TG1) stably overexpressing TET2 in a doxycycline-dependent man-
ner following lentiviral transduction. Q-PCR assays, mean ± SD, 
n = 5 biological samples. e Inhibitory GHB effects on TET2-medi-
ated 5-hmC formation in GMB stem-like TG1 cells overexpressing 
TET2 in a doxycycline-dependent manner, mean ± SD, n = 4 bio-
logical samples. f–h In silico analysis of α-KG (f) and GHB (g) bind-
ing pockets within the TET2 protein. α-KG and GHB are colored in 
white and their oxygens in red. Ribbon representation of TET2 C-ter-
minal domain. Progression from the N- to C- parts of the C-terminal 
domain are colored from blue to orange. h TET2 amino acid residues 
in contact with α-KG or GHB
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production, suggests that this GABA by-product may pro-
mote through a paracrine mode of action the genesis of 
tumor territories enriched in weakly proliferative cells. 
Brain cancer stem-like cells are sensitive to environmen-
tal cues, and epigenetic regulators are known translators 
of extra-cellular cues. Binding sites for factors such as 
YY1, which can interact with major epigenetic regulators 
such as histone methyltransferases [47] and thus translate 
extra-cellular cues, are present in ALDH5A1 gene regula-
tory regions (Ensembl platform, ENSG00000112294). 
The miR-302 can be another relevant epigenetic regulator, 
since it targets ALDH5A1 mRNA, is upregulated in GBM 
stem-like cells by extra-cellular pro-differentiation cues 
[15], and is enriched in non-proliferative/differentiated 
GBM territories (F. Burel-Vandenbos, T. Virolle, unpub-
lished results). Another level of SSADH regulation that 
might be relevant within a tumor context is its sensitivity to 
oxidation. Biochemical studies showed that oxidative stress 
inactivates SSADH through the formation of disulfide 
bonds between cysteine residues of the catalytic domain, 
the enzyme being reactivated upon environmental switch to 
reducing conditions [30]. SSADH expression appears, thus, 
likely to be sensitive to variations in the cell environment, 
but the identity of such extra-cellular cues remains to be 
identified.
Valproate repression of SSADH activity can also be 
relevant in a tumor context. First used as an anti-epileptic 
agent, this pharmacological compound has been found to 
repress proliferation and promote differentiation of differ-
ent cancer cell types and notably of glioblastoma cells [19, 
23]. To our knowledge, we provide the first demonstra-
tion that valproate increases GHB levels in the context of 
cancer. Valproate anti-cancerous action is usually attrib-
uted to its inhibitory effect on histone deacetylases. Our 
results suggest that valproate anti-cancerous effects could 
be mediated at least in part by increased GHB production. 
This therefore adds to the current debate of the potential 
use of valproate as an adjuvant treatment for glioblastoma 
patients [23, 44, 56].
GHB, like GABA, is first known to act through its bind-
ing to GABA receptors [1, 12]. GABA itself has been 
reported to inhibit ESC and NSC proliferation through 
GABAAR activation [3, 16]. Our results with GABAR ago-
nists and antagonists indicate that the restraint exerted by 
GABA on NSC or ESC cycling is absent in GBM stem-like 
cells. Unchanged 5-hmC levels in GHB-treated NSC fur-
ther supports the idea that GHB repressive effects on GBM 
stem-like cell behavior depends on an intra-cellular mode 
of action targeting TET.
TET hydroxylation of methyl groups on cytosine was 
first interpreted as an intermediate step in the process of 
DNA demethylation [17] through passive replication-
dependent demethylation [27] or active enzymatic modi-
fication of the nucleotide [28]. GHB-induced decrease in 
5-hmC formation did not change global DNA methylation 
levels. This observation is consistent with the recent rec-
ognition of 5-hmC as an epigenetic mark per se [50], nota-
bly in the context of pro-neural GBM [51]. This metabolic 
control of GBM stem-like cells is akin to that recently dis-
closed in ESC. Maintenance of high ratios of α-KG over 
TCA metabolites, which might interfere with its role as an 
enzyme cofactor to support TET and additional epigenetic 
modifiers activities, was shown to be essential for prevent-
ing ESC differentiation [8]. Although GHB effects on other 
α-KG dependent epigenetic modifiers cannot be excluded, 
our results demonstrate that TET activity is crucial not only 
for GBM stem-like cells with profiles resembling mesen-
chymal or classical GBM subtypes [55] but also for stem-
like cells isolated from DIPG. These systematically fatal 
tumors are constituted of cells with abundant 5-hmC content 
Fig. 6  Biological effects of TET2 downregulation are comparable to 
GHB treatment or ALDH5A1 downregulation. a TET2 downregula-
tion using siRNA (siTET2) without changes in TET1 or TET3 mRNA 
levels. Q-PCR assay. Mean ± SD, n = 3 independent biological sam-
ples. siC, control siRNA. b–d TET2 downregulation translates into 
decreased 5-hmC levels (b), decreased Nanog immunofluorescent 
(IF) nuclear signal (c), and decreased proliferation (d). TET2 siRNA 
vs control siRNA, mean ± SD, n = 4 independent biological sam-
ples. e Schematic representation of GHB mechanism of action
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distributed through the pons [2], and bear a H3F3.A K27M 
mutation [48, 58] that prevents enzymatic activity of the 
Polycomb repressive complex 2 [6, 33]. Our results show 
that GHB repressive effects on TET activity can take place 
in a context of major deregulation of chromatin modifiers.
Finding that TET inhibition underpins GHB off-tar-
get anti-tumor effect in GBM and DIPG stem-like cells 
stretches out further the variable outcome of TET activ-
ity according to the cancer type considered. TET2 loss-of-
function mutations were identified in myeloid and lymphoid 
hematological malignancies [13], whereas the TET1 over-
expression found in mixed lineage leukemia (MLL)-rear-
ranged leukemia is oncogenic [26]. Context dependency of 
TET (dys)function in cancer is further indicated by lack of 
correlation between 5-hmC levels and IDH1/2 mutations in 
slow growing infiltrative gliomas, although these mutations 
drive overproduction of the 2-HG metabolite that may inter-
fere with α-KG actions as a co-factor [31, 38].
Altogether, our results reveal that switching GABA 
catabolism toward GHB production opposes the prolif-
eration and stem-like properties of GBM and DIPG cells. 
They also show that a neuromodulator can directly interfere 
with an epigenetic modifier. These GHB repressive effects 
are consistent with suppression of GBM cell tumorigenic 
properties upon SSADH downregulation as well as finding 
elevated GHB/α-KG ratios with scarce SSADH expres-
sion in tumor territories characterized by low numbers of 
proliferating cells and lack of Olig2 expression. We, thus, 
uncover a metabolic state with a driving role in repress-
ing aggressiveness of cancer cells in malignant glioma. 
Although no specific SSADH pharmacological inhibitor is 
currently available, the ability of GHB to cross the blood 
brain barrier and its approved use for several indications 
(e.g., narcolepsy, alcohol withdrawal) [12, 29, 36], suggest 
that it could be effective to target cancer cells dependent on 
5-hmC formation for their growth.
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